Eli Lilly and Company ranked No. 5 on the Fair360, formerly DiversityInc Top 50 Companies for Diversity list in 2023.
Eli Lilly and Company completed its acquisition of Versanis Bio. The deal expands Lilly’s portfolio to include Versanis’ lead asset, bimagrumab, which is being used in combination with semaglutide for obese adults.
“Combining our current incretin portfolio, including tirzepatide, with activin receptor blockers such as bimagrumab, could be the next major step in innovative treatments for those living with cardiometabolic diseases, like obesity,” said Ruth Gimeno, Ph.D., group vice president, diabetes, obesity and cardiometabolic research at Lilly. “The wealth of knowledge that our new colleagues from Versanis will bring to Lilly will propel our research and development efforts forward, ultimately benefiting patients around the world.”
